Table 4.

Factors associated with discontinuation of BDZ/Z-drug and successful switch to Melatonin CR in MDD patients with insomnia (univariate and multivariate analysis).

	Univariate analysis		Multivariate analysis
			Model 1 (Age- and gender-adjusted)		Model 2 (Age- and gender-adjusted)
	odds ratio (95%CI)	p-value	odds ratio (95%CI)	p-value	odds ratio (95%CI)	p-value
Age	1.01 (0.97-1.06)	0.49
Gender, female	0.88 (0.42-1.85)	0.73
Occupational status
No	Ref	0.37
Yes	0.61 (0.20-1.80)
Homemakers	0.44 (0.18-1.09)
Years of education	1.06 (0.97-1.15)		1.06 (0.96-1.18)	0.25	1.03 (0.93-1.15)	0.55
HAMD score, total	0.93 (0.88-0.99)	0.018*	0.98 (0.89-1.07)	0.65	–
HAMD score, anxiety/somatization factor	0.78 (0.67-0.92)	0.003**	–		0.85 (0.69-1.05)	0.132
HAMA score, total	0.88 (0.82-0.95)	0.000***	0.86 (0.80-0.93)	0.000***	–
HAMA score, somatic anxiety	0.73 (0.64-0.84)	0.000***	–		0.74 (0.64-0.83)	0.000***
Total duration of BDZ/Z-drug therapy(days)	0.73 (0.63-0.86)	0.000***	0.99 (0.99-1.00)	0.000***	0.99 (0.99-1.00)	0.000***
Time to the first use of antidepressant from initiation of BDZ/Z-drug (days)	0.83 (0.74-0.94)	0.003**	–		0.85 (0.73-0.98)	0.025*
Number of concomitant use of BDZ/Z-drug	0.46 (0.27-0.78)	0.004**	0.58 (0.30-1.13)	0.11	0.51 (0.26-0.97)	0.041*

HAMD, Hamilton depression rating scale; HAMA, Hamilton anxiety rating scale; CI, confidence interval; OR, odds ratio.

*p < 0.05, **p < 0.01, ***p < 0.001.